The proposed research addresses the role of divalent cations in the recognition of fibronectin, an extracellular matrix protein, by its RGD- dependent receptor integrin alpha5beta1 at the structural level. Both macromolecules are central to the regulation of tumor cell proliferation and migration, as well as invasion and metastasis. As in other integrins, the alpha subunit of alpha5beta1 displays repeated amino-acid sequences that have a strong homology with the EF-hands present in calcium-binding proteins, except that the invariant sixth ligand, Glu, is missing in the integrins. In no absence of precise information about the folding of alpha5beta1 integrin, the tertiary structure of recombinant EF-hand fragments will be determined, in the absence and presence of divalent cations, by multidimensional NMR in solution. It has been hypothesized that the aspartyl residue of the fibronectin RGD signal plays the role of the missing ligand in one of the incomplete integrin EF-hands. This hypothesis will be tested with models which involve recombinant alpha5 EF- hands and RGD-containing fibronectin fragments, in the presence of Cd2+, in place of Ca2+, and the fibronectin-integrin contacts will be monitored by 113/Cd NMR. The conformation adopted by the RGD motif in such fibronectin fragments bound to soluble alpha5beta1 integrin will be determined in solution by two-dimensional high-resolution NMR (transferred nuclear Overhauser effect). The determination of the conformation of bound RGD sequences, as well as of the alpha5 EF-hand domain will contribute to our knowledge of the tertiary folding of the alpha5beta1 integrin and will help in the design of novel ligand analogs which could be used for further in vitro and in vivo studies on cell proliferation and migration and in the development of new anti-tumor therapies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA028896-15
Application #
5207099
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
15
Fiscal Year
1996
Total Cost
Indirect Cost
McLean, G W; Brown, K; Arbuckle, M I et al. (2001) Decreased focal adhesion kinase suppresses papilloma formation during experimental mouse skin carcinogenesis. Cancer Res 61:8385-9
Assa-Munt, N; Jia, X; Laakkonen, P et al. (2001) Solution structures and integrin binding activities of an RGD peptide with two isomers. Biochemistry 40:2373-8
Baneres, J L; Roquet, F; Martin, A et al. (2000) A minimized human integrin alpha(5)beta(1) that retains ligand recognition. J Biol Chem 275:5888-903
Ellerby, H M; Arap, W; Ellerby, L M et al. (1999) Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 5:1032-8
Wang, B; Yang, H; Liu, Y C et al. (1999) Isolation of high-affinity peptide antagonists of 14-3-3 proteins by phage display. Biochemistry 38:12499-504
Miura, R; Aspberg, A; Ethell, I M et al. (1999) The proteoglycan lectin domain binds sulfated cell surface glycolipids and promotes cell adhesion. J Biol Chem 274:11431-8
Ruoslahti, E (1999) Fibronectin and its integrin receptors in cancer. Adv Cancer Res 76:1-20
Orend, G; Hunter, T; Ruoslahti, E (1998) Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells. Oncogene 16:2575-83
Kodandapani, R; Veerapandian, L; Ni, C Z et al. (1998) Conformational change in an anti-integrin antibody: structure of OPG2 Fab bound to a beta 3 peptide. Biochem Biophys Res Commun 251:61-6
Arap, W; Pasqualini, R; Ruoslahti, E (1998) Chemotherapy targeted to tumor vasculature. Curr Opin Oncol 10:560-5

Showing the most recent 10 out of 129 publications